Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191,057 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: liu y, liu q. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y, Liu Y, Zhou J, Xu N, Li B, Wu G, Fang J, Li K, Liu X, Liu W, Lu Y, Wang M, Liu W, Liang H, Zhang Y, Huang C, Wang S, Wang Y, Yu S, Chang J, Wang Z, Hu Z, Zhang L. Huang Y, et al. Among authors: liu y, liu x, liu w. Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):576-82. doi: 10.3779/j.issn.1009-3419.2012.10.03. Zhongguo Fei Ai Za Zhi. 2012. PMID: 23075681 Free PMC article. Clinical Trial. Chinese.
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Gong J, Hu B, Zhang X, Zhang F, Zhang J, Xu N, Fan Q, Bai Y, Jiao S, Wang J, Bai C, Zheng L, Shi Y, Liu Y, Liang J, Hu G, Cheng Y, Xu R, Bai Y, Shen L. Gong J, et al. Among authors: liu y. Oncologist. 2014 Feb;19(2):173-4. doi: 10.1634/theoncologist.2013-0137. Epub 2014 Jan 23. Oncologist. 2014. PMID: 24457378 Free PMC article. Clinical Trial.
[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].
Sun Y, Guan Z, Liao M, Yu X, Wang C, Wang J, Niu X, Shi Y, Zhi X, Liu Y, Liu M, Zhang Y, Yang Y, Shen J, Chen G, Zhou Q, Zhou C, Guo Q, Tang L, Duan J, Liang J, Zhang Y, Cheng Y. Sun Y, et al. Among authors: liu y, liu m. Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):57-72. doi: 10.3779/j.issn.1009-3419.2014.02.01. Zhongguo Fei Ai Za Zhi. 2014. PMID: 24581154 Free PMC article. Review. Chinese. No abstract available.
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, Huang C, Yang S, Liu X, Liu Y, Lu S, Wang J, Zhang S, Zhou C, Wang M, Zhang L; INFORM investigators. Zhao H, et al. Among authors: liu y, liu x. J Thorac Oncol. 2015 Apr;10(4):655-64. doi: 10.1097/JTO.0000000000000445. J Thorac Oncol. 2015. PMID: 25546556 Free article. Clinical Trial.
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L. Wang J, et al. Among authors: liu y, liu t. Gastric Cancer. 2016 Jan;19(1):234-44. doi: 10.1007/s10120-015-0457-4. Epub 2015 Jan 21. Gastric Cancer. 2016. PMID: 25604851 Free PMC article. Clinical Trial.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Soria JC, et al. Among authors: liu y. Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6. Lancet Oncol. 2015. PMID: 26159065 Clinical Trial.
191,057 results
You have reached the last available page of results. Please see the User Guide for more information.